National, 2nd December 2025: Ameera Shah-led Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India’s second-largest and the most respected pathology laboratory chain, today announced the launch of three specialised metabolic health packages under its TruHealth portfolio. These have been designed to support individuals preparing for or undergoing GLP-1 based therapies for diabetes, obesity and related metabolic conditions. Developed through rigorous scientific evaluation, the packages offer stage-specific assessments that strengthen therapeutic decision-making and promote long-term metabolic safety. 

India continues to witness a sharp rise in metabolic disorders such as early-onset obesity, insulin resistance, fatty liver disease and elevated cardiovascular risk. With GLP-1 agonists emerging as a preferred therapy for weight management and glycaemic control, consistent metabolic tracking has become essential. Insights from Metropolis’ in-house data indicate a steady increase in abnormal metabolic markers across major cities, underscoring the need for robust, clinically designed monitoring frameworks.

To address this need, Metropolis has introduced three structured, scientifically curated test packages under its GLP-1 series—TruHealth GLP-1 Ready, TruHealth GLP-1 Monitor and the TruHealth GLP-1 Monitor (3-Pack Subscription)—each tailored to distinct pre-therapy and during/post-therapy needs.

TruHealth GLP-1 Ready offers a comprehensive baseline assessment that maps an individual’s metabolic status before initiating GLP-1–based or any advanced weight-management or diabetes intervention, covering glucose–insulin balance, lipid and cardiac risk markers, liver and kidney health and key nutritional indicators. The package also includes vitals and an ECG assessment to offer clinicians a holistic pre-therapy fitness overview.

For individuals already on GLP-1 therapy, TruHealth GLP-1 Monitor provides a dedicated biochemical monitoring framework to track evolving metabolic biomarkers, identify early signs of deficiencies or organ-related changes and support clinicians with timely, data-driven insights for refining treatment decisions. To strengthen continuity and improve long-term outcomes, the TruHealth GLP-1 Monitor (3-Pack Subscription) offers structured evaluations at recommended intervals, giving patients and clinicians a clear longitudinal view of metabolic progress and ensuring interventions remain precise and responsive over time.

Commenting on the launch, Mr. Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited, said: “As GLP-1 therapies gain traction across India, it is increasingly evident that they must be supported by a reliable diagnostic framework. Many individuals start or continue treatment without clear insight into their metabolic status or how their body is responding. These specialised GLP-1 packages address that gap by offering dependable, stage-appropriate assessments that enhance clinical decision-making. Our focus is on making metabolic monitoring accessible and meaningful, enabling safer and more informed care for every patient on a GLP-1 journey.”

Dr. Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare Limited, said:  “Developing meaningful GLP-1 diagnostics requires scientific precision, not just broader test menus. All three packages have been designed through a rigorous test-selection framework aligned with clinical evidence and physician protocols and powered by our high-sensitivity platforms and robust validation systems. This ensures that every parameter included delivers real clinical value—whether assessing metabolic balance, therapeutic response or nutritional status. By emphasising relevance, depth and quality, the TruHealth GLP-1 series offers clinicians reliable insights to guide safe, effective and personalised care.”